Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

被引:10
作者
Wang, Yue [1 ,2 ]
Ung, Matthew H. [2 ]
Cantor, Sharon [3 ]
Cheng, Chao [2 ,4 ,5 ]
机构
[1] Huazhong Univ Sci & Technol, Sch Elect Informat & Commun, Wuhan 430074, Hubei, Peoples R China
[2] Dartmouth Coll, Dept Mol & Syst Biol, Geisel Sch Med, Hanover, NH 03755 USA
[3] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA
[4] Dartmouth Coll, Norris Cotton Canc Ctr, Geisel Sch Med, Lebanon, NH 03766 USA
[5] Dartmouth Coll, Dept Biomed Data Sci, Geisel Sch Med, Lebanon, NH 03766 USA
关键词
GENE-EXPRESSION PROFILES; OVARIAN-CANCER; BRCA2; MUTATIONS; SUSCEPTIBILITY GENE; SIGNATURE; BRCANESS; SURVIVAL; TUMORS; CLASSIFICATION; INHIBITORS;
D O I
10.1038/s41598-017-16138-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
BRCAness has important implications in the management and treatment of patients with breast and ovarian cancer. In this study, we propose a computational framework to measure the BRCAness of breast and ovarian tumor samples based on their gene expression profiles. We define a characteristic profile for BRCAness by comparing gene expression differences between BRCA1/2 mutant familial tumors and sporadic breast cancer tumors while adjusting for relevant clinical factors. With this BRCAness profile, our framework calculates sample-specific BRCA scores, which indicates homologous recombination (HR)-mediated DNA repair pathway activity of samples. We found that in sporadic breast cancer high BRCAness score is associated with aberrant copy number of HR genes rather than somatic mutation and other genomic features. Moreover, we observed significant correlations of BRCA score with genome instability and neoadjuvant chemotherapy. More importantly, BRCA score provides significant prognostic value in both breast and ovarian cancers after considering established clinical variables. In summary, the inferred BRCAness from our framework can be used as a robust biomarker for the prediction of prognosis and treatment response in breast and ovarian cancers.
引用
收藏
页数:15
相关论文
共 69 条
[1]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]   Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].
Audeh, M. William ;
Carmichael, James ;
Penson, Richard T. ;
Friedlander, Michael ;
Powell, Bethan ;
Bell-McGuinn, Katherine M. ;
Scott, Clare ;
Weitzel, Jeffrey N. ;
Oaknin, Ana ;
Loman, Niklas ;
Lu, Karen ;
Schmutzler, Rita K. ;
Matulonis, Ursula ;
Wickens, Mark ;
Tutt, Andrew .
LANCET, 2010, 376 (9737) :245-251
[3]   A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining [J].
Baldeyron, C ;
Jacquemin, E ;
Smith, J ;
Jacquemont, C ;
De Oliveira, I ;
Gad, S ;
Feunteun, J ;
Stoppa-Lyonnet, D ;
Papadopoulo, D .
ONCOGENE, 2002, 21 (09) :1401-1410
[4]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[5]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[6]   Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease [J].
Beral, V ;
Bull, D ;
Doll, R ;
Peto, R ;
Reeves, G .
LANCET, 2001, 358 (9291) :1389-1399
[7]   A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer [J].
Bonome, Tomas ;
Levine, Douglas A. ;
Shih, Joanna ;
Randonovich, Mike ;
Pise-Masison, Cindy A. ;
Bogomolniy, Faina ;
Ozbun, Laurent ;
Brady, John ;
Barrett, J. Carl ;
Boyd, Jeff ;
Birrer, Michael J. .
CANCER RESEARCH, 2008, 68 (13) :5478-5486
[8]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[9]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[10]   Improved survival in women with BRCA-associated ovarian carcinoma [J].
Cass, I ;
Baldwin, RL ;
Varkey, T ;
Moslehi, R ;
Narod, SA ;
Karlan, BY .
CANCER, 2003, 97 (09) :2187-2195